CATALYST PHARMACEUTICALS, INC. (CPRX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Financial Position (from SEC Filings)

$755.9M
Cash & Equivalents
$59.6M
Quarterly Burn Rate
$3,852M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (3 Assets)

DrugPhaseIndications
PERAMPANEL
FYCOMPA 		APPROVED AChR Myasthenia Gravis, Cocaine Addiction, Cocaine Dependence, Cocaine Dependency, Congenital Myasthenic Syndrome, Duchenne Muscular Dystrophy, Lambert-Eaton Myasthenic Syndrome, Methamphetamine Dependence, Muscular Atrophy, Spinal, Myasthenia Gravis, Generalized, Myasthenia Gravis, MuSK, Myasthenic Syndromes, Congenital, Nystagmus, Acquired, Spinal Muscular Atrophy Type 3
VAMOROLONE
AGAMREE 		APPROVED —
AMIFAMPRIDINE PHOSPHATE
FIRDAPSE 		APPROVED —

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CPRX.

SEC EDGAR Filings

All SEC filings for CATALYST PHARMACEUTICALS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.